Figure 4—figure supplement 2. | Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice

Open accessCopyright infoDownload PDFDownload figures

Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice

Figure 4—figure supplement 2.

Affiliation details

University of Washington, United States; Fred Hutchinson Cancer Research Center, United States; University of Missouri, United States
Figure 4—figure supplement 2.
Download figureOpen in new tabFigure 4—figure supplement 2. Effects of 126 ppm eRapa treatment on lifespan in male and female mice.

(A) Survival plots of sex-pooled mice treated with 126 ppm eudragit or eRapa for 90 days starting around 600 days of age. Note: although the curves start at age=0 to represent all of life, we have no data on animals that may have died in this cohort prior to receipt from NIA. Gray box approximately indicates treatment period. N=38 vehicle injected, N=370 eRapa. (B, C) Sex-segregated survival plots of male (B) and female (C) mice fed 126 ppm eudragit or eRapa for 90 days starting around 600 days of age. Note: although the curves start at age=0 to represent all of life, we have no data on animals that may have died in this cohort prior to receipt from NIA. Gray box approximately indicates treatment period. (B) N=20 eudragit males, N=19 126 ppm eRapa males. (C) N=18 eudragit females, N=18 eRapa females.

DOI: http://dx.doi.org/10.7554/eLife.16351.019